Date: 2011-03-29
Type of information: R&D agreement
Compound: biomarkers
Company: Protagen (Germany) Biogen Idec (USA)
Therapeutic area: Autoimmune diseases - Neurodegenerative diseases
Type agreement: Collaboration
R&D
Action mechanism:
Disease: multiple sclerosis
Details: Protagen will be using its UNIarray® Platform to help discover biomarkers in relapsing remitting multiple sclerosis for Biogen Idec, Inc. Under the terms of the agreement, Protagen will apply its UNIarray® technology platform and expertise in autoantibody research to support retrospective analysis of samples from a Biogen Idec clinical trial for the purpose of finding predictive and response biomarkers associated with multiple sclerosis therapy.
This technology platform is used for the development of novel diagnostics based on indication specific autoantibody patterns in patient sera. These indication specific autoantibody patterns were already proven to be present in several autoimmune diseases, but also in cancer and neurodegenerative disorders. The systematic and indication-specific determination of autoantibody patterns will serve as a powerful basis to address hitherto unmet diagnostic needs. UNIarray® serves as platform for the development of product specific companion diagnostics and patient stratification tools for clinical studies.
Financial terms:
Latest news:
